Inject Care Parenterals Private Limited

Inject Care Parenterals Private Limited, established on August 2, 2002, is a private limited company headquartered in Vapi, Gujarat, India. The company specializes in the manufacturing of dry powder penicillin and cephalosporin injectables, serving both domestic and international markets. With an authorized and paid-up capital of ₹32.00 crore, Inject Care Parenterals has demonstrated consistent growth and financial stability.

As of March 31, 2024, the company employed 213 professionals, reflecting its commitment to quality and operational excellence. The leadership team comprises key directors:

• Atish Dilip Patel – Whole-Time Director, appointed on April 11, 2007.
• Alpesh Dilip Patel – Director, appointed on June 14, 2014.
• Dilip Chimanbhai Patel – Director, appointed on April 11, 2007.
• Ashai Dilip Patel – Whole-Time Director, appointed on April 2, 2009.

The company's registered office is located at Plot No. 130 Silvassa Road, Vapi, Gujarat, 396195, India.

Inject Care Parenterals operates a state-of-the-art manufacturing facility in Vapi, Gujarat, India. The plant is designed and constructed in accordance with international standards, ensuring compliance with Good Manufacturing Practices (GMP). The facility boasts a substantial manufacturing capacity, producing 10 million vials per month on a single shift. This high capacity enables the company to undertake contract manufacturing for several large players in both domestic and international markets.

The leadership team at Inject Care Parenterals Private Limited is composed of experienced professionals dedicated to steering the company towards continued success:

• Atish Dilip Patel serves as the Whole-Time Director, having been appointed on April 11, 2007.
• Alpesh Dilip Patel holds the position of Director, with an appointment date of June 14, 2014.
• Dilip Chimanbhai Patel is also a Director, appointed on April 11, 2007.
• Ashai Dilip Patel serves as the Whole-Time Director, with an appointment date of April 2, 2009.

These leaders, along with the company's dedicated team, drive Inject Care Parenterals' commitment to quality and innovation in the pharmaceutical manufacturing sector.

Inject Care Parenterals Private Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Vapi, Gujarat, India, is EU GMP and PIC/s certified, ensuring compliance with international standards.

While specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed, the company's adherence to EU GMP and PIC/s standards indicates a strong foundation for meeting the regulatory requirements of these markets. The substantial manufacturing capacity of 10 million vials per month further positions Inject Care Parenterals to cater to the demands of these regulated markets effectively.

Inject Care Parenterals Private Limited has expanded its reach to emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, enabling the supply of quality pharmaceutical products to a broader patient base. By meeting WHO prequalification criteria, Inject Care Parenterals demonstrates its commitment to global health standards and enhances its competitiveness in emerging markets.

Inject Care Parenterals Private Limited has strategically diversified its geographic footprint, mitigating concentration risks associated with reliance on a single market. The company's expansion into regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan, as well as emerging markets in Africa, Latin America, and Southeast Asia, reflects a comprehensive approach to global market penetration. This diversification strategy not only broadens the company's revenue streams but also positions it to leverage growth opportunities across different regions. The substantial manufacturing capacity of 10 million vials per month supports this expansive geographic strategy, enabling the company to meet the demands of diverse markets effectively.

Specific details regarding Inject Care Parenterals Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to EU GMP and PIC/s standards indicates a commitment to maintaining high-quality manufacturing practices, which are essential for FDA compliance. The substantial manufacturing capacity of 10 million vials per month further suggests the company's capability to meet the demands of regulated markets, including the United States.

Inject Care Parenterals Private Limited's manufacturing facility in Vapi, Gujarat, India, is EU GMP and PIC/s certified, ensuring compliance with international standards. This certification reflects the company's commitment to maintaining high-quality manufacturing practices and positions it favorably for market access in regions that require such certifications.

Inject Care Parenterals Private Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's compliance with CDSCO regulations ensures that its products meet the required quality standards for both domestic and international markets. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to international standards and certifications, such as EU GMP and PIC/s, indicates a robust regulatory compliance framework.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Inject Care Parenterals Private Limited. The company's adherence to EU GMP and PIC/s standards, along with its substantial manufacturing capacity, suggests a proactive approach to regulatory compliance and quality assurance.

Inject Care Parenterals Private Limited operates in a competitive pharmaceutical manufacturing sector, facing competition from both domestic and international companies. Key competitors include Gland Pharma, Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences, and ApiJect. The company's focus on dry powder penicillin and cephalosporin injectables positions it in a specialized niche, allowing for targeted competition. Its adherence to EU GMP and PIC/s standards, along with a substantial manufacturing capacity of 10 million vials per month, provides a competitive edge in meeting the demands of both domestic and international markets.

Inject Care Parenterals Private Limited distinguishes itself through several key strengths:

• Regulatory Compliance: The company's manufacturing facility is EU GMP and PIC/s certified, ensuring adherence to international quality standards.

• Manufacturing Capacity: With a production capacity of 10 million vials per month on a single shift, Inject Care Parenterals can meet substantial market demands and undertake contract manufacturing for large players.

• Product Specialization: The company's focus on dry powder penicillin and cephalosporin injectables allows for specialized expertise and product quality.

Inject Care Parenterals Private Limited's current strategic direction emphasizes the production of generics, particularly in the area of dry powder penicillin and cephalosporin injectables. The company's adherence to international quality standards, substantial manufacturing capacity, and expansion into both regulated and emerging markets position it for sustained growth. Future outlooks suggest a continued focus on quality, regulatory compliance, and market diversification to strengthen its position in the global pharmaceutical manufacturing sector.

Inject Care Parenterals Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on quality and regulatory compliance. The company's substantial export volume and consistent production capacity of 10 million vials per month indicate reliability and the ability to meet large-scale demands.